The Alberta Idealized Throat is an induction port designed for use with with cascade impactors to improve the in vivo relevance of in vitro inhaled product testing.
The product will be launched by Copley Scientific at this year's Drug Delivery to the Lungs conference, which will take place from 8-10 December in Edinburgh, Scotland.
A potential alternative to the standard USP/Ph.Eur induction port currently used for aerodynamic particle size measurement, the Alberta Idealised Throat more closely represents aerodynamic conditions in the human throat, supporting better in vivo/in vitro correlations (IVIVCs) within an R and D environment.
Developed in co-operation with the University of Alberta, Canada, its launch reflects a conference theme of bioequivalence.
New approaches to inhaled product testing will also be in evidence during the EPAG-sponsored workshop on abbreviated impactor measurement (AIM) and efficient data analysis (EDA) concepts in inhaler testing, which will commence with a presentation jointly authored by Jolyon Mitchell (Trudell Medical) and Mark Copley (Copley Scientific).
Pioneering work exploring the use of the Fast Screening Andersen (FSA), an AIM tool, will be presented during the opening session of the conference.
Throughout the three days, Copley Scientific will exhibit the Alberta Idealized Throat, the FSA and the Fast Screening Impactor (FSI), along with other instruments from the company's range of inhaled product test equipment.
Experts from the company will be on hand to discuss trends and advances in in-vitro test methods.
